Terbinafine Tablet
Product Images NDC 70518-4323

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terbinafine (NDC 70518-4323). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Terbinafine 250mg 70518 4323 00)

Terbinafine tablet label showing 250 mg strength with a quantity of 30 tablets. The label includes NDC number 70518-4323, repackaged by RemedyRepack Inc., Indiana, PA. It specifies the tablet is round, white, and provides storage instructions along with manufacturer information for Cipla USA, Inc.*

FDA Label Image

Mm2 (Terbinafine 250mg 70518 4323 01)

Terbinafine 250 mg tablet label showing a quantity of 14 tablets. The label indicates oral dosage form and identifies RemedyRepack Inc. as the repackager. It includes storage instructions, a warning to keep medication away from children, and manufacturer information listed as Cipla USA, Inc., Warren, NJ.*

FDA Label Image

Mm3 (Terbinafine 250mg 70518 4323 02)

Label for Terbinafine Tablet 250 mg oral tablets, with a quantity of 30 tablets. The label includes the NDC number 70518-4323-02 and indicates repackaging by RemedyRepack Inc., Indiana, PA. It also displays storage instructions, the manufacturer's information (Cipla USA, Inc., Warren, NJ), and medication safety warnings.*

FDA Label Image

Image 2 (Terbinafine Str)

Chemical structure of terbinafine hydrochloride, a compound shown with its molecular bonds and rings, representing the active ingredient terbinafine.*

FDA Label Image

Image 1 (Terbinafine Table)

A data table presenting adverse event and discontinuation rates for Terbinafine Tablets compared to placebo. It lists symptoms including headache, gastrointestinal and dermatological symptoms, liver enzyme abnormalities, taste disturbance, and visual disturbance, with corresponding percentages for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.